Comment
Author: Admin | 2025-04-28
Related papersRecurrent pericarditis. Relief with colchicineCirculation, 1990Recurrence is one of the major complications of pericarditis. Treatment of recurrence is often difficult, and immunosupressive drugs or surgery may be necessary. We conducted an open-label prospective study of nine patients (seven men and two women; age, 18-64 years; mean age, 41.7±13.7 years). Patients were treated with colchicine (1 mg/day) to prevent recurrences. All patients had suffered at least three relapses despite treatment with acetylsal- icylic acid, indomethacin, prednisone, or a combination. Pericarditis was classified as idiopathic in five patients, postpericardiotomy in two, post-myocardial infarction in one, and associated with disseminated lupus erythematosus in one. For statistical analysis, we conducted a paired comparison design (Student's t test). All patients treated with colchicine responded favorably to therapy. Prednisone was discontinued in all patients after 2-6 weeks (mean, 26.33±10.9 days), and colchicine alone was continued. After a mean follow-up of 24.3 months (minimum, 10 months; maximum, 54 months), no recurrences were observed in any patient; there was a significant difference between the symptom-free periods before and after treatment with colchicine (pRecurrent pericarditis: mysterious or not so mysterious?European Heart Journal, 2005This editorial refers to 'Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis' † by G. Artom et al., on page 723Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trialThe Lancet, 2014Background Colchicine is eff ective for the treatment of acute pericarditis and fi rst recurrences. However, conclusive data are lacking for the effi cacy and safety of colchicine for treatment of multiple recurrences of pericarditis. Methods We did this multicentre, double-blind trial at four general hospitals in northern Italy. Adult patients with multiple recurrences of pericarditis (≥two) were randomly assigned (1:1) to placebo or colchicine (0•5 mg twice daily for 6 months for patients weighing more than 70 kg or 0•5 mg once daily for patients weighing 70 kg or less) in addition to conventional anti-infl ammatory treatment with aspirin, ibuprofen, or indometacin. Permuted block randomisation (size four) was done with a central computer-based automated sequence. Patients and all investigators were masked to treatment allocation. The primary outcome was recurrent pericarditis in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00235079. Findings 240 patients were enrolled and 120 were assigned to each group. The proportion of patients who had recurrent pericarditis was 26 (21•6%) of 120 in the colchicine group and 51 (42•5%) of 120 in the placebo group (relative risk 0•49; 95% CI 0•24-0•65; p=0•0009; number needed to treat 5). Adverse eff ects and discontinuation of study drug occurred in much the same proportions in each group. The most common adverse events were gastrointestinal intolerance
Add Comment